Zacks Research Has Negative Outlook of BMRN Q2 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Zacks Research lowered their Q2 2026 earnings per share estimates for BioMarin Pharmaceutical in a report released on Wednesday, March 19th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $0.99 per share for the quarter, down from their prior estimate of $1.00. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q3 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $4.09 EPS and FY2027 earnings at $4.79 EPS.

Other equities research analysts have also issued reports about the company. Royal Bank of Canada restated a “sector perform” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Scotiabank upped their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday, February 20th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price on the stock in a report on Monday, February 24th. Citigroup raised their price target on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, Piper Sandler increased their target price on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an “overweight” rating in a research note on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $71.53 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The stock has a market capitalization of $13.65 billion, a P/E ratio of 32.51, a P/E/G ratio of 0.61 and a beta of 0.33. The business has a 50-day moving average of $66.83 and a two-hundred day moving average of $67.78. BioMarin Pharmaceutical has a fifty-two week low of $60.63 and a fifty-two week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The business had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million.

Insider Activity

In related news, CAO Erin Burkhart sold 1,295 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.85% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC acquired a new position in BioMarin Pharmaceutical in the third quarter valued at about $305,000. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at approximately $344,000. Advisors Asset Management Inc. raised its position in shares of BioMarin Pharmaceutical by 1.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company’s stock valued at $805,000 after acquiring an additional 180 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in BioMarin Pharmaceutical by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,401,628 shares of the biotechnology company’s stock worth $98,520,000 after acquiring an additional 55,699 shares during the last quarter. Finally, Swedbank AB grew its holdings in BioMarin Pharmaceutical by 34.7% during the third quarter. Swedbank AB now owns 388,529 shares of the biotechnology company’s stock valued at $27,310,000 after purchasing an additional 100,000 shares during the period. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.